In preclinical models of ACC, two types of drugs targeting the IGF1R, i.e., NVP-AEW541, a selective IGF1R kinase inhibitor and IMC-12, an IGF1R antibody, have been reported to have antiproliferative effects [11, 14], thus encouraging the development of clinical trials in ACC patients using drugs targeting the IGF pathway. The gene discussed is IGF1R; the disease is adrenal cortex carcinoma.